10 source-based articles maintained by the HealthRX.com Editorial Team.
Showing 10 of 10 clinical reviews.
A comprehensive clinical review of tesamorelin's effects on growth, puberty, body composition, and metabolic health in adolescents aged 12 to 17, with safety data and prescribing guidance.
A guide to managing tesamorelin therapy in adolescents aged 12-17, covering school schedules, physical activity, injection timing, storage, and academic performance considerations.
A guide to tesamorelin (Egrifta) use in patients 65 and older, covering dosing adjustments, safety monitoring, IGF-1 targets, and how to manage the transition from adult to geriatric care protocols.
Complete caregiver guide to administering Egrifta (tesamorelin) to adults 65 and older: reconstitution steps, injection technique, storage rules, side-effect monitoring, and when to call the prescriber.
A clinical deep-dive into tesamorelin (Egrifta) use in patients aged 65 and older, covering off-label rationale, trial data, dosing adjustments, safety signals, and how geriatric physiology changes the risk-benefit calculation.
A comprehensive review of tesamorelin (Egrifta) off-label use in pediatric patients under age 12, covering pharmacology, available evidence, safety signals, and what clinicians should know before considering this growth-hormone-releasing hormone analog in young children.
Tesamorelin (Egrifta) carries no FDA approval for patients under 18. This guide covers the pharmacology, the sparse pediatric evidence, dosing considerations, safety signals, and the clinical decision framework HealthRX.com physicians apply when evaluating adolescent off-label requests.
Complete caregiver guidance for administering Egrifta (tesamorelin) to children under age 12, including reconstitution steps, injection technique, storage, side effects, and when to call the prescribing clinician.
A thorough clinical review of tesamorelin (Egrifta) use in children under 12, covering growth plate risks, IGF-1 physiology, regulatory status, and when GHRH analogs are appropriate in pediatric patients.
A clinical guide to transitioning pediatric patients under 12 from tesamorelin-adjacent growth hormone axis therapy into adult endocrine care, covering FDA labeling, GH deficiency guidelines, safety monitoring, and care coordination protocols.